David Carbone, Director of the James Thoracic Oncology Center and Professor of Internal Medicine at The Ohio State University Comprehensive Cancer Center, has dedicated his career to researching and ...
The FDA has extended its approval of UCB’s BIMZELX to three new indications, extending the use of the drug to a total of four ...
UCB and Biogen revealed that their Phase 3 study testing dapirolizumab pegol in people with systemic lupus erythematosus met ...